Skip to main content
Xilio Therapeutics, Inc. logo

Xilio Therapeutics, Inc. — Investor Relations & Filings

Ticker · XLO ISIN · US98422T1007 US Professional, scientific and technical activities
Open in API
Filings indexed 321 across all filing types
Latest filing 2025-11-25 Director's Dealing
Country US United States of America
Listing US XLO

About Xilio Therapeutics, Inc.

https://xiliotx.com/

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing tumor-activated immuno-oncology (IO) therapies for cancer treatment. The company utilizes a proprietary, clinically validated platform to engineer biologics, including antibodies, masked bispecifics, and T cell engagers. These molecules are designed to be 'masked' or inactive in systemic circulation and become fully active only within the tumor microenvironment. This approach aims to concentrate the therapeutic effect precisely on the tumor, thereby minimizing systemic toxicity and improving the efficacy-to-toxicity ratio of potent immunotherapies. Xilio's pipeline consists of multiple clinical and preclinical programs designed to deliver powerful cancer treatments to a broader patient population.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2025-11-25 English
4
Director's Dealing
2025-11-25 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes details about a special meeting of stockholders, approval of a stock incentive plan, repricing of stock options, and voting results. These elements correspond to announcements of changes in management compensation plans and shareholder voting outcomes. The document is not a full annual or quarterly report, nor is it a proxy statement itself, but it references the proxy statement and provides voting results. The key sections are Item 5.02 (Departure/Election of Directors or Officers) and Item 5.07 (Submission of Matters to a Vote of Security Holders). The primary focus is on management-related changes and voting results. Given the detailed voting results and management compensation plan approval, the best fit is Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (6465 characters) and content confirm it is not merely an announcement of a report but contains substantive voting results. Therefore, the classification is DVA with high confidence.
2025-11-25 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-11-14 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-11-14 English
10-Q
Interim / Quarterly Report Q3 2025
2025-11-13 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.